TNG961, a first-in-class, potent and selective HBS1L molecular glue degrader for the treatment of cancers with FOCAD deletion TNG961 is a development candidate targeting HBS1L in FOCAD-deleted ...

BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...

Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

The Company plans to provide a clinical update on TNG260 in the second half of 2025. TNG961, a first-in-class, potent and selective HBS1L molecular glue degrader for the treatment of cancers with ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. By combining the analysis of active enhancer ...

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...

Title: Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers Abstract #: 4252 Session Title: New ...

Scientists have discovered more than a dozen genes that regulate the production of fetal hemoglobin in people of African descent, which may be potential treatment targets for sickle cell disease (SCD) ...